vTv Therapeutics appoints Steven Tuch as CFO, effective Dec 8, 2022

vTv Therapeutics Inc.

Steven Tuch appointed CFO; base salary $450K, target bonus 40% of salary.
Tuch granted options for 500K shares vesting over 3 years; performance equity tied to $50M financing.
Severance: 9 months base salary if terminated without cause or resigns for good reason.
Tuch previously led Rallybio IPO ($92.7M) and 7 years at BMO Capital Markets.
Company preparing for Phase 3 trials of lead candidate TTP399 for type 1 diabetes.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven Tuch

Chief Financial Officer

VTVT · vTv Therapeutics Inc.

Effective: 2022-12-08
Filed: December 13, 2022, 6:59 PM ET

the board of directors of the Company (the “Board”) has appointed Steven Tuch as Chief Financial Officer of the Company, effective as of December 8, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Steven Tuch was appointed as Chief Financial Officer at vTv Therapeutics Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

the board of directors of the Company (the “Board”) has appointed Steven Tuch as Chief Financial Officer of the Company, effective as of December 8, 2022.

View on SEC.gov

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950142-22-003344

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.